Recurrent Disease

GTD is a highly curable disease. Women with hydatidiform mole have an excellent prognosis and women with malignant GTD (called GTN) usually have a very good prognosis. Choriocarcinoma, for example, is an uncommon, yet almost always curable cancer. Although choriocarcinoma is a highly malignant tumor and life-threatening disease, it is very sensitive to chemotherapy. 85-90% of women with low-risk malignant GTD are cured by the initial chemotherapy and the remaining are cured by the use of stronger combinations of drugs or surgery. Similarly, 85-90% of women who develop high-risk malignant GTD are cured by chemotherapy used together with the selective use of surgery and radiation. Approximately 10-15% of women with high-risk malignant GTD will develop drug resistance after prolonged chemotherapy. This group is made up of patients with stage IV disease that involves distant organs such as the brain, liver and bowel. Specially designed chemotherapy treatments using drugs that have been shown to be effective against other cancers are being employed to prolong life for many of these women.

Spotlight

This special section in Self Magazine features a GYN surgeon and 34-year-old (at the time of diagnosis) patient.

Awareness

This year’s National Race to End Women’s Cancer aims to spread the word that all women should Love Your Ladyparts! Check out site’s new features and join the MOVEMENT.

Research

The Foundation’s research award winners will be notified in January. Thank you to all who sent in their applications.

Education

The next Ovarian Cancer Survivors Course will be Saturday, Nov. 1, 2014 in D.C. For more information on educational events and courses, click here.